CoChat

Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection

Open access

Published version of a preprint

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; none of the 52 sources its claims cite is checked for support yet.

Abstract

Gene editing is now routine in all prokaryotic and metazoan cells but has not received much attention in immune cells when the CRISPR-Cas9 technology was introduced in the field of mammalian cell biology less than ten years ago. This versatile technology has been successfully adapted for gene modifications in human myeloid cells and T cells, among others, but applications to human primary B cells have been scarce and limited to activated B cells. This limitation has precluded conclusive studies into cell activation, differentiation or cell cycle control in this cell type. We report on highly efficient, simple and rapid genome engineering in primary resting human B cells using nucleofection of Cas9 ribonucleoprotein complexes, followed by EBV infection or culture on CD40 ligand feeder cells to drive in vitro B cell survival. We provide proof-of-principle of gene editing in quiescent human B cells using two model genes: CD46 and CDKN2A . The latter encodes the cell cycle regulator p16 INK4a which is an important target of Epstein-Barr virus (EBV). Infection of B cells carrying a knockout of CDKN2A with wildtype and EBNA3 oncoprotein mutant strains of EBV allowed us to conclude that EBNA3C controls CDKN2A , the only barrier to B cell proliferation in EBV infected cells. Together, this approach enables efficient targeting of specific gene loci in quiescent human B cells supporting basic research as well as immunotherapeutic strategies.

Overview

CoChat Summary

TL;DR

The paper reports a nucleofection protocol for delivering Cas9 ribonucleoproteins into resting primary human B cells, achieving CD46 knockout in >85% of cells and enabling functional studies of Epstein-Barr virus infection. Using this approach, the authors confirm that EBNA3C represses CDKN2A/p16INK4a as a barrier to EBV-driven B cell proliferation, but do not find evidence that EBNA3A/C block plasma cell differentiation in newly infected primary B cells.

Key findings

  • Nucleofection of two CD46-Cas9 RNPs into primary human B cells yielded ~60% knockout with individual gRNAs and regularly ≥85% with both, at DNA and CD46 surface-protein levels; viability was typically 70–80%. Comparable CD46 knockout was obtained from PBMC-derived B cells and with CD40L/IL-4 expansion, and editing did not require EBV infection.
  • In non-infected B cells, CD46 indel frequency was >70% at 16 h and up to 85% at 72 h; in EBV-infected cells, knockout reached 60% at 24 h and plateaued at ~85%, with CD46-negative cells rising from ~10% at 24 h to >85% at day 8. At 24 h after nucleofection, 47.8% of CD46 exon 2 RNA reads were unaltered, 17.6% had mutations, and 34.6% had ~98-nt deletions; CD46 transcription was reduced 0.73-fold, with no major global transcriptome impact and no detectable IFN-α release.
  • Targeting CDKN2A exon1α gave knockout efficiency ~60–80%. In mixed cultures (10–20% p16 KO initially), ΔEBNA3C EBV-infected cells showed gradual enrichment of CDKN2A-negative cells exceeding 80% after 8 weeks, whereas WT EBV-infected populations did not show a clear trend. p16INK4a-negative cells infected with ΔEBNA3C EBV continued to proliferate beyond ~5–6 weeks, while p16-positive cells ceased to proliferate and died.
  • In p16 KO cells infected with ΔEBNA3A/C EBV, flow cytometry after up to two months showed no substantial differences in CD20, CD38, and CD138 versus WT EBV-infected controls; CD138 differences were significant but very low and no CD138high subpopulation was seen, so the authors did not recapitulate EBNA3A/C blockade of plasma cell differentiation.

Methods

  • Primary human B cells were isolated from adenoid biopsies or PBMCs/buffy coats; 2×10^6 cells were nucleofected with in vitro assembled Cas9 RNPs (tracrRNA/crRNA plus S. pyogenes Cas9 V3) using Lonza P3 buffer and the EH100 program, then infected with WT or mutant EBV (6008, 6123 ΔEBNA3C, 6331 ΔEBNA3A/C) at MOI 0.1 green Raji units or cultured on CD40L feeder cells with IL-4.
  • Knockout was quantified by next-generation sequencing of PCR amplicons analyzed with Outknocker 2.0; surface protein and immunophenotype by flow cytometry; newly transcribed RNA by 4sU labeling and RNA-seq on NextSeq500 (2×150 bp, 15.7–18.6 million reads/sample); IFN-α by ELISA. Statistics used Prism v7.0, Wilcoxon signed-rank test, and one-way ANOVA where indicated.
  • For CDKN2A experiments, WT and p16 KO cells were mixed at 10–20% KO, infected with WT or ΔEBNA3C EBV, and tracked by NGS and cell expansion; differentiation markers CD20/CD38/CD138 were compared with WT EBV-infected controls and RPMI-8226 as positive control.

Limitations

  • Stated: the paper notes that overall RNA yield from 4sU labeling was very low, although quality control confirmed high-quality libraries; it also states that the specific gene locus and gRNA design may strongly affect outcome, and that some GO/GSEA results were less conclusive.
  • Stated: the paper reports that its results with newly infected primary B cells appear to differ from previous work on EBNA3A/C-mediated blockade of plasma cell differentiation, and it does not recapitulate that phenotype; the reason is stated as unknown.
  • Evident from the text: long-term editing readouts depend on EBV infection or CD40L/IL-4 culture to prevent rapid apoptosis of primary B cells, so editing in truly resting B cells without such survival support was not assessed; some experiments (e.g., IFN-α ELISA, one CDKN2A time course) used two biological replicates, and transcriptome analysis used three donors.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.ppat.1009117

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Targeting the locus of the cell surface protein CD46 in primary human B cells. (A) Schematic overview of the delivery of CD46-Cas9 RNP complexes to primary human B cells by nucleofection. 2×106 primary human B cells were nucleofected with RNP complexes assembled with a two-component guide RNA (gRNA) protocol using tracrRNA, crRNA and recombinant Streptococcus pyogenes Cas9 nuclease. The cells recovered for 1 h after nucleofection before they were infected with wild-type (WT) EBV. The efficiency of gene editing was analyzed at the level of nucleotide sequence and surface protein. (B) Indel frequencies derived from next generation sequencing analysis of the second exon of the CD46 gene are shown together with flow cytometry analysis of CD46 protein expression from all investigated samples. Cells were nucleofected with individual Cas9 RNP complexes (gRNA1 or 2) or concomitantly with both complexes and were analyzed 1 week later. Mean and standard deviation from four independent biological replicates are shown. (C) Flow cytometry analysis of CD46 surface staining of living cells treated with two RNP complexes 1 week post infection.
Fig 1 Targeting the locus of the cell surface protein CD46 in primary human B cells. (A) Schematic overview of the delivery of CD46-Cas9 RNP complexes to primary human B cells by nucleofection. 2×106 primary human B cells were nucleofected with RNP complexes assembled with a two-component guide RNA (gRNA) protocol using tracrRNA, crRNA and recombinant Streptococcus pyogenes Cas9 nuclease. The cells recovered for 1 h after nucleofection before they were infected with wild-type (WT) EBV. The efficiency of gene editing was analyzed at the level of nucleotide sequence and surface protein. (B) Indel frequencies derived from next generation sequencing analysis of the second exon of the CD46 gene are shown together with flow cytometry analysis of CD46 protein expression from all investigated samples. Cells were nucleofected with individual Cas9 RNP complexes (gRNA1 or 2) or concomitantly with both complexes and were analyzed 1 week later. Mean and standard deviation from four independent biological replicates are shown. (C) Flow cytometry analysis of CD46 surface staining of living cells treated with two RNP complexes 1 week post infection.CC BY · PubMed Central
Fig 2 The kinetics of induced DNA breaks and their repair in the second exon of CD46 in non-infected and EBV-infected primary human B cells. (A) Primary human B cells were nucleofected with the two CD46-Cas9 RNP complexes and analyzed 16, 24, 48 and 72 hours later. The cells were left non-infected. At the indicated time points viable cells were selected by Ficoll gradient centrifugation. Part of the CD46 locus in their cellular DNA was amplified in a two level PCR barcoding scheme prior to next generation sequencing. Data were analyzed using the Outknocker 2.0 web tool. The results showed a indel frequency of 70% in primary human B cells 16 h after nucleofection in the absence of EBV infection. Indel frequencies increased up to 90% 72 h after nucleofection. Mean and standard deviation of independent biological replicates are shown. (B) The time course experiments show the indel frequencies in the second exon of CD46 in EBV infected primary B cells after nucleofection with two CD46-Cas9 RNP complexes. Cellular DNA of viable cells was amplified in a two level PCR barcoding scheme prior to next generation sequencing and the data were analyzed with the Outknocker 2.0 web tool. Indel frequencies increased up to 85% 8 days after nucleofection. Mean and standard deviation of independent biological replicates are shown. (C) CD46 flow cytometry analyses of primary B cells 1, 4 and 8 days after nucleofection with two CD46-Cas9 RNP complexes and subsequent infection with WT EBV are shown. Mean and standard deviation of independent biological replicates are provided. (D) Scheme of metabolic labeling of newly transcribed RNAs with 4sU and their analysis by next generation sequencing. 2×107 primary human B cells were nucleofected with two CD46-Cas9 RNP complexes. Nucleofected (CD46-Cas9) as well as adjusted numbers of untreated (WT) B cell samples were infected with wild-type (WT) EBV. 23 hours after nucleofection, newly transcribed RNAs were metabolically labeled with 4sU for 1 hour. After RNA extraction, biotinylation of newly transcribed 4sU labeled RNAs and their enrichment, cDNA libraries were established and sequenced on a NextSeq500 (Illumina) instrument with 2x150 bp paired end reads. 15.7 to 18.6 Mio reads per sample were obtained. (E) An MA plot shows the differentially expressed genes in CD46-Cas9 vs. WT B cell samples following EBV infection and 4sU labeling 24 hours after B cell preparation. Log2-fold changes and mean of normalized read counts were plotted on the y- and x-axes, respectively. 182 differentially expressed genes are designated by magenta dots. Green dots highlight the CD46 gene and genes involved in the different pathways of DNA repair. Ongoing transcription at the CD46 locus was intact in CD46-Cas9 RNP complex nucleofected cells but reduced by a factor of 0.73 24 h after nucleofection. (F) IFN-α release of primary B lymphocytes after RNP nucleofection. B cells nucleofected with the CD46-Cas9 RNP complexes or cells nucleofected with P3 buffer, only, were cultured with or without WT EBV infection overnight. On the next day, the cells were counted and re-seeded with identical cell numbers. After 48 hours, supernatants were collected and IFN-α was measured by ELISA. As positive controls, uninfected cells were treated with different concentration of the TLR9 agonist ODN2216 for 20 hours prior to analysis. The threshold level of detection was 10 pg/ml IFN-α as indicated by the dashed line. P values were calculated using the one-way ANOVA test. ***, P<0.001, **, P<0.01. Mean and standard deviation of two biological and technical replicates are shown. (G) Shown are three schematic examples of mapped reads aligned to the hg19 reference sequence together with the two RNP complex target sites (chr1: 207,930,419–207,930,438 and chr1: 207,930,497–207,930,516) at exon 2 of the CD46 gene. Reads with unmodified exon 2 (WT) sequences, reads with nucleotide mutations (indels, i.e. base changes or small insertions and deletions), reads with deletions in between the two annotated RNP complex target sites and their percentages are shown.
Fig 2 The kinetics of induced DNA breaks and their repair in the second exon of CD46 in non-infected and EBV-infected primary human B cells. (A) Primary human B cells were nucleofected with the two CD46-Cas9 RNP complexes and analyzed 16, 24, 48 and 72 hours later. The cells were left non-infected. At the indicated time points viable cells were selected by Ficoll gradient centrifugation. Part of the CD46 locus in their cellular DNA was amplified in a two level PCR barcoding scheme prior to next generation sequencing. Data were analyzed using the Outknocker 2.0 web tool. The results showed a indel frequency of 70% in primary human B cells 16 h after nucleofection in the absence of EBV infection. Indel frequencies increased up to 90% 72 h after nucleofection. Mean and standard deviation of independent biological replicates are shown. (B) The time course experiments show the indel frequencies in the second exon of CD46 in EBV infected primary B cells after nucleofection with two CD46-Cas9 RNP complexes. Cellular DNA of viable cells was amplified in a two level PCR barcoding scheme prior to next generation sequencing and the data were analyzed with the Outknocker 2.0 web tool. Indel frequencies increased up to 85% 8 days after nucleofection. Mean and standard deviation of independent biological replicates are shown. (C) CD46 flow cytometry analyses of primary B cells 1, 4 and 8 days after nucleofection with two CD46-Cas9 RNP complexes and subsequent infection with WT EBV are shown. Mean and standard deviation of independent biological replicates are provided. (D) Scheme of metabolic labeling of newly transcribed RNAs with 4sU and their analysis by next generation sequencing. 2×107 primary human B cells were nucleofected with two CD46-Cas9 RNP complexes. Nucleofected (CD46-Cas9) as well as adjusted numbers of untreated (WT) B cell samples were infected with wild-type (WT) EBV. 23 hours after nucleofection, newly transcribed RNAs were metabolically labeled with 4sU for 1 hour. After RNA extraction, biotinylation of newly transcribed 4sU labeled RNAs and their enrichment, cDNA libraries were established and sequenced on a NextSeq500 (Illumina) instrument with 2x150 bp paired end reads. 15.7 to 18.6 Mio reads per sample were obtained. (E) An MA plot shows the differentially expressed genes in CD46-Cas9 vs. WT B cell samples following EBV infection and 4sU labeling 24 hours after B cell preparation. Log2-fold changes and mean of normalized read counts were plotted on the y- and x-axes, respectively. 182 differentially expressed genes are designated by magenta dots. Green dots highlight the CD46 gene and genes involved in the different pathways of DNA repair. Ongoing transcription at the CD46 locus was intact in CD46-Cas9 RNP complex nucleofected cells but reduced by a factor of 0.73 24 h after nucleofection. (F) IFN-α release of primary B lymphocytes after RNP nucleofection. B cells nucleofected with the CD46-Cas9 RNP complexes or cells nucleofected with P3 buffer, only, were cultured with or without WT EBV infection overnight. On the next day, the cells were counted and re-seeded with identical cell numbers. After 48 hours, supernatants were collected and IFN-α was measured by ELISA. As positive controls, uninfected cells were treated with different concentration of the TLR9 agonist ODN2216 for 20 hours prior to analysis. The threshold level of detection was 10 pg/ml IFN-α as indicated by the dashed line. P values were calculated using the one-way ANOVA test. ***, P<0.001, **, P<0.01. Mean and standard deviation of two biological and technical replicates are shown. (G) Shown are three schematic examples of mapped reads aligned to the hg19 reference sequence together with the two RNP complex target sites (chr1: 207,930,419–207,930,438 and chr1: 207,930,497–207,930,516) at exon 2 of the CD46 gene. Reads with unmodified exon 2 (WT) sequences, reads with nucleotide mutations (indels, i.e. base changes or small insertions and deletions), reads with deletions in between the two annotated RNP complex target sites and their percentages are shown.CC BY · PubMed Central
Fig 3 Read coverage of 4sU labeled transcripts shows a reduced transcription in cells 24 hours after CD46-Cas9 RNP complex nucleofection only at exon 1 and 2 of CD46. (A) The upper plot shows the primary, unspliced transcript of the CD46 gene together with its nucleotide coordinates on chromosome 1 and the 14 exons (dashed, vertical lines) of the CD46 transcript (x-axis). The normalized read coverage at single nucleotide resolution is shown (y-axis) from WT cells (blue line) and CD46-Cas9 treated cells (red line). The lower graph depicts the mRNA data of exon 1 to 8 of the CD46 transcript covering the two conditions. Read normalization of the three pairs of replicates was performed as stated in Materials and Methods. (B) The plots show the primary transcript positions (bp) (x-axis) vs. the normalized read coverage at single nucleotide resolution of four selected transcripts (CD46, ATN1, DICER, FCRL5). Transcript data (y-axis) from WT cells (blue line) and CD46-Cas9 nucleofected cells (red line) are shown. Plots indicated ‘189 nts’ visualize the 189 nt long exons of the ATN1, DICER and FCRL5 transcripts together with the second exon of the CD46 transcript. Plots of the last exons of the four transcripts are shown for comparison. The two dashed vertical lines in the plot of the second exon of CD46 indicate the positions of the Cas9 mediated cleavage sites.
Fig 3 Read coverage of 4sU labeled transcripts shows a reduced transcription in cells 24 hours after CD46-Cas9 RNP complex nucleofection only at exon 1 and 2 of CD46. (A) The upper plot shows the primary, unspliced transcript of the CD46 gene together with its nucleotide coordinates on chromosome 1 and the 14 exons (dashed, vertical lines) of the CD46 transcript (x-axis). The normalized read coverage at single nucleotide resolution is shown (y-axis) from WT cells (blue line) and CD46-Cas9 treated cells (red line). The lower graph depicts the mRNA data of exon 1 to 8 of the CD46 transcript covering the two conditions. Read normalization of the three pairs of replicates was performed as stated in Materials and Methods. (B) The plots show the primary transcript positions (bp) (x-axis) vs. the normalized read coverage at single nucleotide resolution of four selected transcripts (CD46, ATN1, DICER, FCRL5). Transcript data (y-axis) from WT cells (blue line) and CD46-Cas9 nucleofected cells (red line) are shown. Plots indicated ‘189 nts’ visualize the 189 nt long exons of the ATN1, DICER and FCRL5 transcripts together with the second exon of the CD46 transcript. Plots of the last exons of the four transcripts are shown for comparison. The two dashed vertical lines in the plot of the second exon of CD46 indicate the positions of the Cas9 mediated cleavage sites.CC BY · PubMed Central
Fig 4 p16INK4a is a functional barrier to EBV driven proliferation of lymphoblastoid cells. (A) Blueprint of the primary transcript and the spliced mRNA with the three exons of CDKN2A on chromosome 9 encoding the p16INK4a protein. The target site of the RNP complex within the 1st exon (exon1α) (chr9:21,974,678–21,974,827) is shown. (B) Study of the biological effect of the CDKN2A knockout in a time course experiment. WT and p16 KO cells were mixed such that the fraction of the latter was in the order of 10 to 20%, when the cells were infected with WT or ΔEBNA3C EBV strains. The knockout status of the CDKN2A gene was studied by next generation sequencing to analyze the CD46 locus of the mixed cell populations over time. The fraction of cells with a disabled CDKN2A gene increased in cells infected with ΔEBNA3C EBV exceeding 80% after eight weeks, whereas the knockout status of CDKN2A in the population of cells infected with WT EBV did not show a clear trend. Results from two biological replicates are shown, additional replicates can be found in S4A Fig. (C) Cell numbers of four different B cell populations were plotted as a function of days post nucleofection (x-axis) versus the format of the cell culture vessel (y-axis) starting with a single well in a 48-well cluster plate. 2×106 B cells with an intact CDKN2A locus (WT cells) or cells with an edited CDKN2A gene (p16 KO cells) were infected with wild-type (WT) EBV (left panel) or ΔEBNA3C EBV (right panel). WT EBV infected primary human B cells developed into stably expanding lymphoblastoid cell lines irrespective of their p16INK4a status (left panel). ΔEBNA3C EBV infected B cells could be expanded until about six weeks p.i., when cells with an intact CDKN2A gene ceased to proliferate and were lost eventually (right panel). In contrast, ΔEBNA3C mutant EBV infected p16INK4a negative B cells continued to proliferate beyond this time point. The results were consistent between four different biological replicates. Other replicates are shown in S4B Fig. (D) p16 KO cells infected with ΔEBNA3A/C EBV and WT cells infected with WT EBV were analyzed for CD20, CD38 and CD138 cell surface levels by flow cytometry. The graph summarizes the mean fluorescence intensities (MFI) of CD20, CD38 and CD138 markers of living cells two months post infection. Mean and standard deviation obtained from 8 independent biological replicates are shown. The significance of MFI values of the immunophenotypic surface proteins was calculated using the Wilcoxon matched-pairs signed rank test.
Fig 4 p16INK4a is a functional barrier to EBV driven proliferation of lymphoblastoid cells. (A) Blueprint of the primary transcript and the spliced mRNA with the three exons of CDKN2A on chromosome 9 encoding the p16INK4a protein. The target site of the RNP complex within the 1st exon (exon1α) (chr9:21,974,678–21,974,827) is shown. (B) Study of the biological effect of the CDKN2A knockout in a time course experiment. WT and p16 KO cells were mixed such that the fraction of the latter was in the order of 10 to 20%, when the cells were infected with WT or ΔEBNA3C EBV strains. The knockout status of the CDKN2A gene was studied by next generation sequencing to analyze the CD46 locus of the mixed cell populations over time. The fraction of cells with a disabled CDKN2A gene increased in cells infected with ΔEBNA3C EBV exceeding 80% after eight weeks, whereas the knockout status of CDKN2A in the population of cells infected with WT EBV did not show a clear trend. Results from two biological replicates are shown, additional replicates can be found in S4A Fig. (C) Cell numbers of four different B cell populations were plotted as a function of days post nucleofection (x-axis) versus the format of the cell culture vessel (y-axis) starting with a single well in a 48-well cluster plate. 2×106 B cells with an intact CDKN2A locus (WT cells) or cells with an edited CDKN2A gene (p16 KO cells) were infected with wild-type (WT) EBV (left panel) or ΔEBNA3C EBV (right panel). WT EBV infected primary human B cells developed into stably expanding lymphoblastoid cell lines irrespective of their p16INK4a status (left panel). ΔEBNA3C EBV infected B cells could be expanded until about six weeks p.i., when cells with an intact CDKN2A gene ceased to proliferate and were lost eventually (right panel). In contrast, ΔEBNA3C mutant EBV infected p16INK4a negative B cells continued to proliferate beyond this time point. The results were consistent between four different biological replicates. Other replicates are shown in S4B Fig. (D) p16 KO cells infected with ΔEBNA3A/C EBV and WT cells infected with WT EBV were analyzed for CD20, CD38 and CD138 cell surface levels by flow cytometry. The graph summarizes the mean fluorescence intensities (MFI) of CD20, CD38 and CD138 markers of living cells two months post infection. Mean and standard deviation obtained from 8 independent biological replicates are shown. The significance of MFI values of the immunophenotypic surface proteins was calculated using the Wilcoxon matched-pairs signed rank test.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 40 Not checked · 69 Own results and interpretations

50 more claims

Create a free account to see all 109 claims and to verify the 52 references still open.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 51 references

Cited by

Metadata

Authors
Akidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O. T., & Hammerschmidt, W.
Affiliations
  • Helmholtz Munich (DE)
  • German Center for Infection Research (DE)
Corresponding author
Hammerschmidt, Wolfgang
Venue
PLOS Pathogens
Published
2021-04-15
Volume
17
Issue
4
Pages
e1009117
ISSN
  • 1553-7366 (ISSN-L)
  • 1553-7374
OpenAlex
W3155357417
Cited by
31
References
51
Citations by year
2026: 4 · 2025: 7 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 3
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • PLoS Pathogens (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • Site cant be reached (submittedVersion, cc-by)
Funders
  • Deutsche Krebshilfe (70112875)
  • Deutsches Zentrum für Infektionsforschung (07.814)
  • Deutsche Forschungsgemeinschaft (SFB1064/TP A13)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
CRISPR/Cas9, gene knockout, Epstein-Barr virus infection, nucleofection, Cas9 ribonucleoprotein, resting B cells, CDKN2A, p16INK4a, EBNA3C, CD46, B cell proliferation
MeSH terms
Gene Editing, B-Lymphocytes, Herpesvirus 4, Human, Humans, Lymphocyte Activation, Viral Proteins, Virus Latency, Epstein-Barr Virus Nuclear Antigens, Epstein-Barr Virus Infections, Gene Knockout Techniques, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.